Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of JZP441 in Sleep-Deprived Healthy Participants
NCT05651152Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in narcolepsy and idiopathic hypersomnia (IH) comparing JZP441 with Placebo (2 arms). Primary endpoint: Treatment-emergent Adverse Events. Started Nov 2022; status: completed.
02
Drugs
JZP441
03
Conditions
narcolepsyidiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT05651152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651152.